Skip to content

Public FDA record

Z-0516-2024: The 4Kscore Test, an in vitro serum or plasma test that combines the results of four immunoassays (Roche

Recall record Z-0516-2024 for BioReference Health, LLC. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-0516-2024
Company in FDA record
BioReference Health, LLC
FDA classification date
Dec 8, 2023
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class II

Reason stated in the source

Mathematical modeling of the 4Kscore with and without DRE information was recently performed on over 3,000 specimens. DRE information is a required component of The 4Kscore Test.

Source facts

Action
A notification letter dated 10/31/23 was sent to customers. As of the FDA approval of 4Kscore in December 2021, only results with a digital rectal examination (DRE) input of Nodule or No Nodule are considered as valid. Customers who received 4Kscore results without having DRE information inputted (e.g., no information entered for Nodule or No Nodule ) are advised that these results may have increased uncertainty, potentially resulting in erroneous decision interpretations, as DRE information is required for the interpretation recommendations contained in the PMA approved device labeling. The device has now been modified such that if the required DRE information is not provided (e.g., no information entered for Nodule or No Nodule ), then the blood sample will be frozen and stored at our laboratory for up to 60 days, and 4Kscore results will not be performed unless the required DRE information is provided within 60 days. As per the package insert, the DRE cannot be performed within 96 hours before sample collection, but it can be performed after phlebotomy, or in the preceding 12 months before testing. If it is more convenient to schedule the DRE in an office visit after the blood draw, blood samples will be frozen and stored at our laboratory for up to 60 days. The required DRE information can be provided to our customer service center within that me, and the sample will be tested once this information is received. No results will be reported if the input of Nodule or No Nodule information is not received by 60 days. If there are any questions, please feel free to reach out by telephone: 1-833-4KSCORE (1-883-457-2673), Fax: 201-663-4113, or email: 4kcustomerservice@bioreference.com. Thank you again for allowing BioReference Health to assist you in the care of your patients with potential prostate cancer. Please respond using the page following this letter, by fax 201-663-4113, or email: 4kcustomerservice@bioreference.com to confirm receipt of thi
Initiated
2023-10-31
Root cause
Device Design
Distribution
US Nationwide distribution.
Recall number
Z-0516-2024
Recall status
Open, Classified
CDRH record ID
203329
FDA classified
2023-12-08
Recall event number
93050

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗